Hosted on MSN1mon
Is Vertex Pharmaceuticals Stock Underperforming the Dow?Valued at a market cap of nearly $120.6 billion, the company’s lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi, and Kalydeco, which are collectively approved to treat people with CF.
Hosted on MSN1y
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Revenues in fourth-quarter 2023 are likely to have ...
Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback